Basic information of CCL4 :
| Official Symbol of Gene | CCL4 |
| Species | Homo sapiens |
| Entrez Gene ID | 10630 |
| Official Full Name | C-C motif chemokine ligand 4 |
| Also known as | ACT2; G-26; HC21; LAG1; LAG-1; MIP1B; SCYA2; SCYA4; MIP1B1; AT744.1; MIP-1-beta |
| Gene Type | protein coding |
| dbXrefs | Ensembl:ENSG00000275302 MIM:182284; AllianceGenome:HGNC:10630 |
| Map Location | 17q12 |
Sample information of multiple sclerosis:
| Detected Sample | peripheral blood |
| Sample Detail | N/A |
| Detected Method | RT-qPCR |
| Disease | MS |
| Disease subtype | RRMS |
| Population | N/A |
| Sample Size | healthy donors (n = 15), untreated (n = 13), and laquinimod-treated patients with MS (n = 14) |
Literature information of multiple sclerosis :
| Pubmed ID | 33203651 |
| Year | 2020 |
| Title | Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS |
Results of multiple sclerosis :
| Expression | down-regulation |
| Risk type | Disease risk |
| Result | The secretion of TNF-α, IL-6, IL-10, and MIP-1β was reduced in LPS-stimulated monocytes of laquinimod-treated patients with MS compared with HDs, but not in comparison to untreated patients with MS |
| Mechanism/Pathway | laquinimod-associated inhibition of the NF-κB pathway |
